Madrigal Pharmaceuticals-Madrigal (MDGL) Reports Q4 Loss, Tops Revenue Estimates

Madrigal (MDGL) came out with a quarterly loss of $2.71 per share versus the Zacks Consensus Estimate of a loss of$ 4.12. This compares to loss of $5.68 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 34.22%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 6.94 per share when it actually produced a loss of $4.92, delivering a surprise of 29.11%.Over the last four quarters, the company h ...